N/A N=50 Proton Therapy for Early Stage Breast Cancer
Early-Stage Breast Cancer
Primary: Ipsilateral Breast Tumor Recurrence-free Survival — 92 percentage of patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=39 Thoracoscopic Sentinel Lymph Node Biopsy in Patients With Stage I or Stage II Breast Cancer
Breast Cancer
Primary: Success Rate in Removing Sentinel Lymph Nodes by Thoracoscopy — 31 participants
Phase 2 N=37 Neoadjuvant Endocrine Therapy in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Node-Negative Breast Cancer
Breast Cancer · Invasive Breast Cancer
Primary: Change in Baseline of Cancer Cell Protein Levels of Human Epidermal Growth Factor Receptor (HER) Family Members (HER1-4) Following Neoadjuvant Endocrine Therapy. — 1…
N/A N=206 Cryoablation of Low Risk Small Breast Cancer- ICE3 Trial
Breast Cancer
Primary: Local Inbreast Breast Tumor Recurrence (IBTR) Rate — 4.3 Percentage of participants with IBTR
N/A N=1,832 Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer
Breast Cancer
Primary: Overall Survival — 82; 83 percentage of alive at 10 years — p=0.38
Phase 2 N=257 Preoperative Treatment of Breast Cancer With Two Different Sequential Treatment Regimens
Breast Cancer
Primary: Number of Participants With a Pathological Complete Response — 21; 24; 99; 89 participants
Phase 2 N=270 Breast-Conserving Surgery and Radiation Therapy in Patients With Multiple Ipsilateral Breast Cancer
Breast Cancer
Primary: Local Recurrence — 3.1 percentage of participants
Phase 2 N=100 Partial Breast Irradiation (PBI) for Selected Patients With Early Breast Cancer
Breast Neoplasms
Primary: Feasibility of PBI Directed External Radiotherapy as Measured by Percentage of Participants Achieving a Dosimetrically Satisfactory Treatment Plan — 100; 100 percentage…
N/A N=162 Tumor: Breast Ratio Study
Breast Cancer · LCIS · DCIS
Primary: Quality of Life as Measured by the Breast Q — 61.9; 57.6; 74.2; 64.2 score on a scale
Phase 2 N=61 Letrozole in Post-Menopausal Patients With Operable Hormone-Sensitive Breast Cancer
Breast Cancer Female
Primary: Measure Ki67 Index in Highly Hormone-dependent Breast Cancers vs. Those That Are Not — 7; 6; 40 Participants
Phase 2 N=25 Partial Breast Irradiation With Chemotherapy
Breast Cancer
Primary: Number of Participants Experiencing Acute, Late Skin, and Subcutaneous Toxicity — 0 Participants
N/A N=256 Early Surgery or Standard Palliative Therapy in Treating Patients With Stage IV Breast Cancer
Breast Cancer · Stage IV Breast Cancer
Primary: 3-year Overall Survival Rate — 67.9; 68.4 percentage of participants — p=0.32
N/A N=50 Single Fraction High-Gradient Partial Breast Irradiation in Treating Patients With Low-Risk Stage 0-I Breast Cancer
Breast Neoplasms
Primary: Percentage of Patients Who Are Free of Serious Treatment Related Toxicity — 50; 49 Participants
Phase 2 N=51 Randomized Phase II Trial Induction Therapy for Early Stage Breast Cancer
Breast Cancer
Primary: Number of Participants With Complete Pathologic Response Rate to Pre-operative Treatment in Arm A (Docetaxel for 4 Cycles Followed by Capecitabine for 4 Cycles) or Arm B…
Phase 2 N=36 Preoperative Hormone Therapy for Postmenopausal Women With ER+ Clinical Stage T2-4 Tumors
Breast Cancer · Stage II Breast Cancer · Stage III Breast Cancer
Primary: Overall Response Rate as Measured by Clinical Exam, Standard Imaging, and Surgical Pathology Findings — 23; 0 Participants
Phase 2 N=158 Anastrozole and Letrozole After Surgery for the Treatment of Stage I-III Breast Cancer
Anatomic Stage I Breast Cancer AJCC v8 · Anatomic Stage IA Breast Cancer AJCC v8 · Anatomic Stage IB Breast Cancer AJCC v8
Primary: Percentage of Participants With Adequate Estrogen Suppression After 8 Weeks of Adjuvant Anastrozole 10 mg Daily — 76.0 percentage of participants
N/A N=934 Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases
Breast Cancer
Primary: 5-year Disease-Free Survival — 84.4; 87.8 percentage of participants — p=0.004
Phase 2 N=26 Exemestane or Docetaxel-Cytoxan in Low Recurrence Score Cancers
Breast Cancer
Primary: Pathologic Complete Response — 5; 1; 4; 2 Participants
N/A N=324 Partial Breast Irradiation (PBI) for Selected Patients With Early Invasive or Non-Invasive Breast Cancer
Ductal Breast Cancer
Primary: Feasibility and Local Control of Early Breast Cancer Treated by Partial Breast Irradiation Using Different Radiation Doses Determined by Completion. — 98; 101; 124…
Phase 2 N=17 Paclitaxel, Cyclophosphamide & Doxorubicin, Autologous Dendritic Cells & Surgery in Stage II/III Breast Cancer (Women)
Breast Cancer
Primary: Number of Patients With Pathological Complete Response — 2 participants
Phase 2 N=83 Neoadjuvant Treatment With Nab-paclitaxel for Patients With Stage II and III Luminal Breast Cancer
Breast Cancer
Primary: The Residual Cancer Burden Grade III (RCB-III). — 23; 37; 14; 6 Participants
Phase 2 N=756 Surgery to Remove the Sentinel Lymph Node and Axillary Lymph Nodes After Chemotherapy in Treating Women With Stage II, Stage IIIA, or Stage IIIB Breast Cancer
Breast Cancer
Primary: False Negative Rate (FNR) for Sentinel Lymph Node (SLN) Surgery After Chemotherapy When at Least 2 SLNs Were Excised in Women Initially Presenting With Biopsy-proven cN1…
Phase 2 N=102 Hypofractionated Radiation Therapy in Treating Patients With Stage 0-IIB Breast Cancer
Ductal Breast Carcinoma In Situ · Invasive Breast Carcinoma · Stage 0 Breast Cancer
Primary: Percentages of Participants by EORTC Breast Cosmetic Rating Score at 24 Months Post-radiation Therapy — 17; 26; 24; 11 Participants
Phase 2 N=180 Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer
Stage 0 Breast Cancer AJCC v6 and v7 · Stage I Breast Cancer AJCC v7 · Stage IA Breast Cancer AJCC v7
Primary: Percent Change in Time of Circulating Estradiol SPE in Each Arm — -89; -85; -60 percent change
Phase 3 N=622 Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer
Breast Cancer
Primary: Clinical Response (Complete or Partial Response) Rate (Cohort A) — 62.9; 74.8; 69.1 percentage of patients
Phase 1 N=87 A Study of LY3484356 in Women With Breast Cancer Before Having Surgery
Breast Cancer
Primary: Percent Change From Baseline in Estrogen Receptor (ER) Expression — -88.89; -81.50; -70.13 percent change
Phase 3 N=2,980 Adjuvant Tamoxifen Compared With Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ
Breast Cancer
Primary: Number of Participants With Breast Cancer Recurrence, Including Recurrent DCIS and New Contralateral Tumours — 103; 120 Participants — p=0.33
Phase 2 N=60 Feasibility Study of Intraoperative Imaging in Breast Cancer
Breast Cancer
Primary: (Phase A Only) Selection of Dose of LUM015 to be Used in Future Breast Trials — 2.1; 4.7; 4.2 Ratio
N/A N=46 4D Image-Guided Partial Breast Radiation in Stage 0 and l Breast Cancer
Breast Cancer
Primary: Patients With Reduction in Incidental Radiation — 46 Participants
N/A N=252 Educational Program in Younger Women Who Have Recently Finished Treatment for Stage I or Stage II Breast Cancer
Breast Neoplasms
Primary: Depressive Symptoms (Measured With an Abbreviated 10-item CES-D) at Baseline, Post-intervention (4-months Post-intervention) and Final Follow-up (13-months…